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ABSTRACT
We carried out a retrospective observational study of 264 HER2-positive advanced breast cancer (ABC)
patients to explore the efficacy of first-line treatment with pertuzumab/trastuzumab/taxane in real-
world setting. Survival data were analyzed by Kaplan Meier curves and log rank test.
Median follow-up, length of pertuzumab/trastuzumab/taxane treatment and of pertuzumab, trastu-
zumab maintenance were 21, 4 and 15 months, respectively. The response rate was 77.3%, and the
clinical benefit rate 93.6%. Median progression-free survival (mPFS) was 21 months, and median overall
survival (mOS) was not reached.
When comparing patients by trastuzumab-pretreatment, similar PFS were observed, although a
longer OS was reached in trastuzumab-naïve patients (p = 0.02). Brain metastases at baseline and
their development in course of therapy were associated with significantly shorter PFS (p = 0.0006) and
shorter OS, although at a not fully statistically relevant extent (p = 0.06).
The addition of maintenance endocrine therapy (ET) to pertuzumab/trastuzumab maintenance was
associated with longer PFS (p = 0.0001), although no significant differences were detected in OS
(p = 0.31). Results were confirmed by propensity score analysis (p = 0.003 and p = 0.46, respectively).
In multivariate models, longer PFS was related to lower Performance Status (PS) (p = 0.07), metastatic
stage at diagnosis (p = 0.006) and single metastatic site (p < 0.0001). An OS advantage was observed
with lower PS (p < 0.0001), single metastatic site (p = 0.004), no prior exposure to trastuzumab
(p = 0.004) and response to pertuzumab-based treatment (p = 0.003). Our results confirm that trastu-
zumab/pertuzumab/taxane is the standard of care as first-line treatment of patients with HER2-positive
ABC even in the real-world setting. Moreover, the double-maintenance therapy (HER2 block and ET) is
strongly recommended when feasible.
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Introduction
Human epidermal growth factor receptor 2 (HER2) overex-
pression and gene amplification are represented in approxi-
mately 15–20% of breast cancers and are associated with
increased aggressiveness, poor prognosis and shorter
survival.1 In the advanced setting, the combination of che-
motherapy, particularly taxanes and trastuzumab, a monoclo-
nal antibody directed against membrane HER2 receptor, is
able to determine high response rate and prolonged survival.-
2,3 Since the use of anthracycline in combination with trastu-
zumab showed increased risk of cardiotoxicity,1,4 alternative
trastuzumab-based combinations have been used and have
shown some efficacy in the advanced setting, e.g., vinorelbine,
capecitabine, gemcitabine, letrozole or anastrozole.5-10
Trastuzumab-based triple combinations (i.e. trastuzumab
+ 2 chemotherapeutic agents) did not show advantage over
double combinations (trastuzumab + 1 chemotherapeutic
drug),11,12 thus, the standard first-line treatment was the
combination of a taxane and trastuzumab. In the Cleopatra
phase III randomized trial, Pertuzumab, a novel HER2 tar-
geted humanized monoclonal antibody, showed, in combina-
tion with trastuzumab and docetaxel, a clear advantage both
in progression free survival (PFS) and overall survival (OS)
compared with trastuzumab and docetaxel.13-15 These results
led to the approval of this regimen as definite first-line treat-
ment for advanced HER2 positive breast cancer.
Subsequently, a phase II study confirmed the efficacy and
safety of pertuzumab, trastuzumab and weekly paclitaxel, as
first and second-line treatment for advanced disease.16
So far, the combination of trastuzumab/pertuzumab and a
taxane is considered the gold standard of first-line treatment
in HER2 positive advanced breast cancer. Few and generally
limited in size preliminary reports in patients treated outside
of clinical trials seem to confirm the efficacy and tolerability
of this regimen.17,18 Since patients treated in prospective ran-
domized trials are usually selected based on strict inclusion/
exclusion criteria, and do not necessary exemplify the real-life
setting, we carried out a large retrospective observational
study of advanced HER2 positive breast cancer patients trea-
ted as first-line treatment with pertuzumab/trastuzumab/tax-
ane combination at several Italian cancer centres.
Results
Overall, we retrospectively evaluated 264 HER2 positive
advanced breast cancer patients, treated with pertuzumab/
trastuzumab and taxanes (docetaxel, 205/264, paclitaxel, 59/
264), from September 2012 through August 2017 at 22 Italian
cancer centres.
Main patient and tumor characteristics are listed in
Table 1. In brief, median age was 53 years, median ECOG
PS was 0. Ninety-seven patients (97/264; 36.7%) were pre- and
167/264 (63.3%) patients were post-menopausal at baseline.
Seventy-nine (79/264) patients had tumors with both hormo-
nal receptors negative, 53/264 patients had tumor expressing
one hormonal receptor, and 132/264 patients had “triple
positive” (ER, PgR, HER2 positive) tumors.
One hundred forty-five (145/264) patients had received
previous neoadjuvant (53/264) or adjuvant (92/264) che-
motherapy regimens, inclusive of trastuzumab in 30/53 and
71/92 patients, respectively. Ten (10/264) patients had not
received previous trastuzumab in the early setting because
diagnosed before its registration. Thirteen (13/264) patients
had received endocrine therapy without chemotherapy, in
combination with trastuzumab, in the adjuvant setting.
Among the 264 patients evaluated, 145 (54.9%) had recur-
rent disease, with a median disease-free interval of 53 months
(range, 7–342), whereas 119 patients (45.1%) had de novo
metastatic disease. At treatment starting, 61.7% of our patients
had visceral metastases, 12.9% bone-only lesions, 7.9% asymp-
tomatic brain metastases, and 48.1% had multiple metastatic
sites.
Treatment received
All the patients received pertuzumab-based regimens as
first-line chemotherapy treatment for HER2 positive
advanced disease, and were evaluable for treatment efficacy.
Median follow up was 21 months (range, 3–59). Median
pertuzumab/trastuzumab and chemotherapy duration was
4 months (range, 1–16), with a median number of che-
motherapy cycles of 6 (range, 1–9). In more detail, the
median number of administered docetaxel cycles was 6
(range, 1–20) and the median number of weekly paclitaxel
administrations was 16 (range, 2–33). Discontinuation of
taxanes was most commonly due to cumulative haematolo-
gical toxicity.
After the discontinuation of chemotherapy, 234 (88.6%)
patients received pertuzumab/trastuzumab maintenance
therapy, with a median duration of 15 months (range,
2–43), with 46% of the patients having been treated for
more than 12 months in absence of disease progression.
Endocrine maintenance treatment together with pertuzu-
mab/trastuzumab administration was given to 103 (39%)
patients, who represented the 55.6% of the endocrine recep-
tor positive tumors. Brain radiotherapy was administered in
30 patients on maintenance therapy with pertuzumab and
trastuzumab, while 10 patients had already been treated
with radiation therapy for brain metastases before starting
the first-line treatment. Through the follow up period,
pertuzumab/trastuzumab maintenance treatment was dis-
continued in 144 (54.6%) patients. The most common rea-
sons for discontinuation were disease progression (109
patients), toxicity (10 patients), patient decision (8 patients)
or medical decision (17 patients).
Efficacy
Overall, we observed 40 complete responses (CR) (15.2%) and
169 partial responses (PR) (64%), for an overall response rate
(ORR) of 77.3% (95%CI, 72.2–82.3) (Table 2). A stable disease
(SD) was recorded in 15.5% of these patients. A clinical
benefit (CB), defined as response or stable disease lasting at
least 6 months, was observed in 247 patients (93.6%, 95%CI,
90.6–96.5). As showed in Table 3, not fully significant
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differences were observed when we analyzed objective
responses according to ER/PgR status (p = 0.06).
Among those patients who were metastatic at diagnosis
(119), we observed 18 CR (15.1%) and 81 PR (68.1%), for
an ORR of 83.2% (95%CI, 76.5–89.9), and a CB rate of 95.8%
(95%CI, 92.2–99.4). Among the 75 patients having received
previous neoadjuvant/adjuvant trastuzumab, we observed 12
CR (16%), and 46 PR (61.3%), with an ORR of 77.3% (95%CI,
67.8–86.8). Stable disease was recorded in 15 patients (20%),
and CB was reported in 72 patients (96%; 95%CI, 91.6–100).
No differences in ORR emerged when we compared trastuzu-
mab-naïve and pretreated patients (p = 0.64).
Overall response rate was slightly higher in patients with
visceral metastases (83.4%), compared with other metastatic
sites (74.6%), or bone-only involvement (67.6%), although at a
not statistically significant extent (p = 0.07). In patients with
baseline brain metastases (21 patients) ORR was 52.4%, while
it was 81.5% in their counterpart (p = 0.002).
In our case series, a significant difference in response
rate was observed between the type of taxane administered
in combination with pertuzumab/trastuzumab, being ORR
82.9% with docetaxel and 66.1% with paclitaxel
(p = 0.005).
All but 30 patients (27 due to progressive disease, 1 due to
cardiotoxicity, 2 lost to follow-up) after chemotherapy dis-
continuation had received trastuzumab/pertuzumab as main-
tenance therapy. Overall, 37/234 patients (15.8%) further
improved their response (Supplementary Table 1).
Among the 169 patients with ER and/or PgR positive tumors
having received pertuzumab/trastuzumab maintenance, 103
(60.9%) patients received in addition endocrine maintenance
therapy. Among them, 18 patients (17.5%) showed further
improvement of response. Conversely, in 66 patients receiving
only pertuzumab/trastuzumab without hormonal treatment,
response rate was further improved in 8 cases (12.1%)
(p = 0.39). In this subgroup of patients, the median length of
trastuzumab/pertuzumab maintenance therapy was 8 months
(range, 1 to 37), with a median length of maintenance endocrine
therapy of 11 months (range, 1 to 55). Central nervous system as
site of disease progression was observed in 33 patients without
previous brain metastases (13.6%), and in 12 patients (57.1%)
with baseline brain metastases.
Long-term outcomes
Overall, in these 264 patients, median PFS was 21 months
(95%CI, 17–25), whereas median OS was not reached
(Figure 1). Rates of 1-year PFS and 2-year OS were also
computed and reported in Table 4. No statistical differences
were observed when we analyzed PFS and OS according to
Table 1. Main baseline characteristics of the study population (N:264).
Characteristics
Patients, N
(%)
Age
Median (range) 53 (29–80)
Histology
Ductal 234 (88.6)
Lobular 9 (3.4)
Other 21 (8.0)
Metastatic at diagnosis
Yes 119 (45.1)
Not 145 (54.9)
Grading
1–2 82 (31.1)
3 141 (53.4)
Unknown 41 (15.5)
ER and/or PgR positive at initial diagnosis
Yes 183 (69.3)
Not 81 (30.7)
HER2-positive at initial diagnosis
Yes 225 (85.2)
No 39 (14.8)
HER2-status at study entry
IHC 2+ (ISH amplified) 57 (21.6)
IHC 3+ 156 (59.1)
Positive, unknown 51 (19.3)
Subtype at study entry
Triple-positive 132 (50)
ER or PgR positive 53 (20.1)
ER and PgR negative 79 (29.9)
ECOG Performance Status
0 185 (70.1)
1 69 (26.1)
2 10 (3.8)
Neoadjuvant chemotherapy
Yes 53 (20.1)
No 211 (79.9)
Adjuvant chemotherapy
Yes 92 (34.8)
No 172 (65.2)
Neoadjuvant trastuzumab
Yes 30 (11.4)
No 234 (88.6)
Adjuvant trastuzumab
Yes 71 (26.9)
No 193 (73.1)
Adjuvant hormonal therapy
Yes 89 (33.7)
No 175 (66.3)
Adjuvant radiotherapy
Yes 87 (33.0)
No 175 (67.0)
Metastatic sites
Visceral 163 (61.7)
Brain 21 (7.9)
Bone-only 34 (12.9)
Number of metastatic sites
1 137 (51.9)
2 74 (28.0)
≥3 53 (20.1)
Type of taxane associated with pertuzumab-
trastuzumab
Paclitaxel weekly 59 (22.3)
Docetaxel every three weeks 205 (77.7)
Abbreviations: N, number; ER estrogen receptor, PgR, progesterone receptor
Table 2. Best responses to pertuzumab-based treatment.
Best responses, Number (%)
Complete response 40 (15.2)
Partial response 169 (64)
Stable Disease 41 (15.5)
Progressive Disease 14 (5.3)
Total 264 (100)
Table 3. Best responses to pertuzumab-based treatment according to molecular
subtype.
Responses
Complete
response
N (%)
Partial
response
N (%)
Stable
Disease
N (%)
Progressive
Disease
N (%)
Triple-positive 14 (10.6) 89 (67.4) 22 (16.7) 7 (5.3)
ER or PgR positive 6 (11.3) 38 (71.7) 8 (15.1) 1 (1.9)
ER and PgR negative 20 (25.3) 42 (53.2) 11 (13.9) 6 (7.6)
Chi square test: p = 0.06
Abbreviations: N, number; ER estrogen receptor, PgR, progesterone receptor
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hormonal receptors expression or not (p = 0.57 and p = 0.23,
respectively). Comparable median PFS were reached when
groups were compared by trastuzumab pretreatment, being
17 months in pretreated and 23 months in naïve patients
(p = 0.10). Conversely, a longer OS was observed in trastuzu-
mab naïve patients (p = 0.02). Visceral involvement or bone-
only metastases did not impact PFS (p = 0.40 and 0.10,
respectively) or OS (p = 0.58 and 0.70, respectively).
In patients without brain metastases at baseline we
observed a longer median PFS (26 months; 95%CI, 22–30),
compared to patients with known brain metastases
(20 months; 95%CI 13–27) or patients who developed
brain metastases in course of pertuzumab-based treatment
(13 months; 95%CI, 9–17) (p = 0.0006). Accordingly, rates of
2-year OS were 83.9% in patients without brain metastases at
baseline, 77.7% in patients with documented brain metas-
tases, and 65.6% in patients who developed brain metastases
while on treatment.
The type of taxane administered in combination with
pertuzumab/trastuzumab had no significant impact on
long-term outcomes, being PFS and OS similar (p = 0.44
and p = 0.47, respectively). Maintenance endocrine therapy,
added to maintenance pertuzumab and trastuzumab, was
associated with longer median PFS, being 28 months (95%
CI, 26–31), versus 17 (95%CI, 13–21) months in patients
without maintenance endocrine therapy, respectively
(p = 0.0001) (Figure 2(a,b)). Conversely, no differences
have been observed to date in OS according to maintenance
endocrine treatment (p = 0.31). Results were confirmed
when adjusting for propensity score, with a median PFS
of 17 months (95%CI, 12–22) in patients who did not
receive hormonal therapy and 29 months (95%CI, 25–33)
in patients who received hormonal therapy (p = 0.003). No
differences were observed in OS according to maintenance
endocrine treatment (p = 0.46) (Figure 2(c,d)).
No significant differences were observed in median PFS
according to HER2 hyperexpression/amplification
(p = 0.18). Conversely, HER2 status impacted OS, with
rates of 2-year OS of 63.9% in patients with HER2 2+/ampli-
fied tumors and 85.1% in patients with HER2 3+ tumors. In
patients with HER2 2+/amplified tumors, no differences in
median PFS were observed depending on double mainte-
nance treatment (p = 0.12). Conversely, in the HER2 3+ sub-
set, maintenance endocrine therapy added to double HER2
block led to a longer PFS (p = 0.02). In terms of OS, no
statistical differences were seen, even if patients with HER2 2
+/amplified tumors who received maintenance endocrine
therapy showed a non-significantly longer OS (p = 0.15).
Figure 1. Progression-Free Survival (a) and Overall Survival (b) in the overall population.
Table 4. 1-year PFS and 2-year OS according to tumor and patient
characteristics.
Characteristics N
1-year
PFS p 2-year OS p
Overall 264 67.2 - 80.5 -
Molecular subtype
Triple-positive 53 72.9 87.8
ER or PgR positive 132 66.7 80.1
ER and PgR negative 79 63.7 0.57 76.3 0.23
Trastuzumab pretreatment
yes 75 58.0 67.5
no 189 70.8 0.10 85.6 0.02
Visceral involvement
Yes 163 62.8 79.6
No 101 74.5 0.4 81.7 0.58
Bone-only metastases
Yes 34 76.3 85.0
No 230 65.9 0.10 79.9 0.70
Brain metastases
No 210 69.6 83.9
Yes, pretreatment 21 70.8 77.7
Yes, during pertuzumab
treatment
33 51.0 0.0006 65.6 0.06
Type of taxane
administered
Docetaxel 205 65.0 79.4
Paclitaxel 59 74.8 0.44 84.7 0.47
Maintenance ET
Yes 103 83.2 89.5
No 67 59.6 0.0001 76.9 0.31
HER2 status
3+ 156 73.1 85.1
2+, amplified 57 60.7 0.18 63.9 0.002
HER2 2+, maintenance ET
Yes 26 79.8 85.4
No 16 56.3 0.12 49.2 0.15
HER2 3+, maintenance ET
Yes 58 86.7 87.5
No 33 61.7 0.02 82.4 0.62
Abbreviations: ET, endocrine therapy; PFS, progression free survival; OS, overall
survival
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In patients with HER2 3+ tumors, endocrine maintenance
treatment had no impact in terms of OS (p = 0.62) (Table 4).
In multivariate analysis (Table 5), a PFS benefit was asso-
ciated with lower PS (p = 0.07), metastatic setting at diagnosis
(p = 0.006) and presence of a single metastatic site (p < 0.0001).
Parameters related to an OS advantage were lower PS
(p < 0.0001), presence of a single metastatic site (p = 0.004), no
prior treatment with trastuzumab (p = 0.004) and a clinical
response to pertuzumab-based treatment (p = 0.003).
Overall, no new safety concerns were identified. The most
common adverse events were diarrhea, rash, mucosal inflamma-
tion and pruritus. No episodes of febrile neutropenia were
reported. After the discontinuation of taxanes, the incidence of
all adverse events decreased considerably. Unfortunately, we are
unable to provide more extensive information on safety.
Regarding cardiotoxicity, all the recruited patients had a base-
line a LVEF > 50%. Overall, 25 patients (9.4%) experienced
cardiac toxicity of any grade. Cardiotoxicity resulted in permanent
discontinuation of treatment in 9 patients (3.4%).
Discussion
Our analysis supports the efficacy of first-line treatment with
pertuzumab, trastuzumab and docetaxel/paclitaxel in a non-
selected population of HER2 positive advanced breast cancer
patients, with a response rate of 77.3%, a CB of 93.6%, and a
median PFS of 21 months. Our results are consistent with the
findings from the Cleopatra trial.14
There are some differences between our patient population
and patients enrolled in the Cleopatra trial. In regard to patients
pretreated with trastuzumab in the early setting, in our study they
were 75 (28.4%), whereas in the pivotal trial they were 47 (11.7%).
Moreover, in our patient population there were less patients with
visceral lesions (61.7% versus 78.1%), more patients had hormo-
nal receptor positive disease (70.1% versus 47.0%), and 103 (39%)
patients received maintenance endocrine treatment, which was
not allowed in the Cleopatra trial. Furthermore, patients with
Figure 2. Progression-free survival (PFS, a) and overall survival (OS, b) according to administration of maintenance hormonal therapy and adjusted for propensity
score (PFS, c; OS, d) .
Table 5. Multivariate analysis.
PFS HR IC95% P
Performance status (1–2 vs 0) 1.39 0.97–1.99 0.07
Metastases at diagnosis (no vs yes) 1.63 1.15–2.32 0.006
N° of metastatic sites (≥2 vs 1) 2.04 1.44–2.89 <0.0001
OS HR IC95% P
Performance status (1–2 vs 0) 3.09 1.72–5.56 <0.0001
N° of metastastatic sites (≥2 vs 1) 2.49 1.34–4.61 0.004
Pretreatment with Trastuzumab (yes vs no) 2.36 1.31–4.25 0.004
Response to treatment (no vs yes) 2.54 1.38–4.65 0.003
Abbreviations: HR, hazard ratio; IC95%, confidence interval; N°, number; PFS,
progression free survival; OS, overall survival
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baseline brain metastases were included in our analysis, whereas
were excluded from the registrative trial. In our patient population
the use of docetaxel was associated with higherORRs compared to
paclitaxel, i.e., 82.9% versus 66.1% (p = 0.005). This latter differ-
ence did not translate into long-term outcome, andmay be related
to different tumor and patient characteristics, or to the choice of
paclitaxel in frail patients with more extensive metastatic
involvement.
Overall, maintenance endocrine therapy was added to
maintenance pertuzumab/trastuzumab in 103 patients. As
expected, this subgroup of patients, receiving both mainte-
nance treatments, had the most favorable long-term outcome,
with a median PFS of 28 months, and a 2-year OS of 89.5%.
The use of a propensity score minimized the chances that the
differences observed between the groups compared were dri-
ven by unevenly distributed baseline characteristics for the
patients included, and increased our confidence in this study
results. These latter data are not comparable with the results
from the pivotal trial, since in the Cleopatra trial maintenance
endocrine treatment was not allowed. We thus relied on the
phase II PERTAIN study, which evaluated the benefit of
adding pertuzumab to trastuzumab plus an aromatase inhibi-
tor in women with locally advanced or metastatic hormone
receptor–positive, HER2-positive breast cancer. Compared to
trastuzumab plus endocrine therapy alone, the addition of
pertuzumab yielded a statistically significant 3-month prolon-
gation of PFS and more durable responses19.
The differences observed in long-term outcomes by HER2
status (2+ amplified or 3+) in the present trial are probably
related to the observational nature of the study and limited
number of patients included in this subset analysis. Our con-
fidence toward this specific result is additionally lessened by
the high number of participating centers and lack of a cen-
tralized revision for HER2 status.
When globally considered, our results favorably compare
with those from the registrative trial. Nevertheless, it is worth
underlying that the present findings are observed in an unse-
lected patient population. As such, our study patients showed
comorbidities (more often represented by hypertension, dia-
betes, obesity and hypothyroidism), and/or involvement of
unfavorable metastatic sites, such as brain metastases at base-
line. In addition, our analysis included data on a considerable
number of patients with early recurrence or who recurred
after previous trastuzumab in the early setting.
We reported a comparable efficacy of the regimen of
interest in subgroups differing by trastuzumab-pre-treatment,
with a median PFS of 17 months, compared with 23 months
observed in trastuzumab naïve patients (p = 0.10), even if a
higher rate of 2-year OS (85.6% vs 67.5%) was observed in
trastuzumab naïve patients.
Data concerning the efficacy of trastuzumab-based first-
line treatment in patients relapsing after neo/adjuvant trastu-
zumab are still controversial, even if there is a trend towards a
lower benefit in patients recurring after adjuvant/neoadjuvant
trastuzumab.20,21 The combination of pertuzumab and trastu-
zumab seems to be superior to the use of one single HER2
targeted agent.13,14,22 Indeed, pertuzumab is thought to
potentiate trastuzumab effect by preventing dimerization of
HER2, stimulating antibody-dependent cell-mediated
cytotoxicity (ADCC) and, due to the different HER2 epitopes
as site of binding, pertuzumab is supposed to exert synergistic
action with a more complete block of HER2 signaling.23,24 A
phase II study with pertuzumab and trastuzumab without
chemotherapy in 66 pretreated patients who developed dis-
ease progression while on trastuzumab-based therapy showed
ORR and CB of 24.2% and 50%, with a median PFS of
5.5 months, confirming the efficacy of adding pertuzumab
to trastuzumab even in heavily pretreated patients progressing
under trastuzumab-based regimens.25 In the Cleopatra trial,
the small subset of patients previously exposed to trastuzumab
in the early setting, i.e., 88 patients, had substantially the same
favorable outcome in PFS (HR 0.62) than trastuzumab naïve
patients (HR 0.60),13 thus suggesting the advantage of adding
pertuzumab even in patients failing early trastuzumab-based
treatments. Moreover, in the registrative trial, there is an OS
advantage in the pertuzumab arm even in trastuzumab pre-
treated patients (HR 0.68).14
In our patient population there was a subset of early
recurred patients (while on or before 12 months from adju-
vant trastuzumab completion, N:14; 5.3%), whereas in the
Cleopatra trial there was a 12 month-interval between trastu-
zumab end and study enrollment. Notwithstanding these dif-
ferences, even in this subset of patients, treatment did not
show lower efficacy. Unfortunately, we do not have data on
subsequent treatment-lines, which may have influenced OS
results.
Another key point is the length of the taxane-based
chemotherapy associated with pertuzumab/trastuzumab
administration. In our study, the median duration of doc-
etaxel therapy was shorter than in the Cleopatra trial (6 vs
8 cycles, respectively), with similar results in efficacy. In the
registrative study, at least six cycles of docetaxel were
recommended (13). In this setting, the use of chemotherapy
is not a matter of debate. However, decisions concerning
the number of docetaxel cycles should be taken at the
individual patient level and in light of considerations perti-
nent to the performance status, burden of disease, and
toxicity. Moreover, maintenance therapy with pertuzumab
and trastuzumab extends the efficacy of treatment without
relevant adverse events. In HER2+/ER+ tumors, our data
also show that the addition of endocrine maintenance ther-
apy to pertuzumab/trastuzumab improves long term out-
comes and represents a suitable option in patients who do
not tolerate chemotherapy.
A retrospective study has recently evaluated 155 patients
treated with trastuzumab/pertuzumab and a taxane as first-
line treatment at 8 Italian centers, and compared results with
those from the Cleopatra trial.17 Patients enrolled in this
observational trial had more frequently endocrine positive
tumors, less visceral metastases and more patients had
received adjuvant trastuzumab. The median number of doc-
etaxel cycles was 7, and median PFS was 27.8 months, with no
relevant differences in term of efficacy across the subgroups
analyzed. This latter PFS estimate is higher than that in the
registrative trial, possibly reflecting differences in tumors and
patients characteristics, endocrine maintenance treatment, but
also different timing in disease re-evaluation between rando-
mized trials and clinical practice.
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Another retrospective observational study investigated the
outcome of HER2 positive advanced breast cancer patients
treated in real-world oncology practice with pertuzumab as
first-line treatment.18 Two hundred and forty-nine (249)
patients received trastuzumab, pertuzumab and taxane as
first-line for advanced disease. Sixty-one percent (61%) had
previously received neoadjuvant/adjuvant trastuzumab, and
60% of these patients had hormonal receptor positive tumors.
The median number of pertuzumab cycles was 11 (range,
1–41), with a median duration of 7.3 months (range, 0.7–
29). Two-hundred and twenty-six patients received docetaxel,
21 paclitaxel, and 2 nab-paclitaxel. The median number of
docetaxel cycles was 6 (range, 1–27). Subsequently, about 25%
of patients with hormonal receptor positive tumors received
endocrine therapy. Median PFS was 16.9 months, with an
estimated 1 year PFS rate of 62%.
A recent metanalysis has evaluated the efficacy and safety of
pertuzumab-based treatment in advanced HER2 positive breast
cancer patients. It included 5 randomized clinical trials invol-
ving 3,742 patients. Overall, the regimen pertuzumab/trastuzu-
mab/docetaxel was associated with a significant reduction in
death (HR: 067, 95%CI, 0.57–0.78) and an improved OS (HR
0.66, 95%CI 0.35–0.67), and PFS (HR 0.64, 95%CI 0.58–0.71),
without a significant increase in cardiotoxicity.26
Our study has some limitations. First, the length of follow
up was relatively short and overall insufficient to draw firm
conclusions in terms of OS. More generally, our results must
be interpreted in light of multiple biases and weaknesses
mainly, though not exclusively, stemming from our study
design, i.e., retrospective, observational design. Our study
further lacked detailed data on toxicity and patients’ co-mor-
bidities. Missing data represent a common limitation in the
conduct of studies including patients from real life setting,
since the systematic collection of data may not easily comply
with the activities related to the clinical routine. Our study
also has some relevant strengths, since it provides evidence in
support of the activity of trastuzumab, pertuzumab and a
taxane-regimen in real-world practice and, to our knowledge,
it is the largest observational case series made available thus
far. Moreover, our results suggest the relevant and favorable
impact of endocrine maintenance treatment in patients with
endocrine receptor positive tumors, and in patients with prior
exposure to trastuzumab in the early setting.
Our results support the administration of trastuzumab,
pertuzumab, and taxane as first-line treatment of patients
with HER2 positive advanced breast cancer in every-day clin-
ical practice. Furthermore, to our knowledge, this is the study
with the largest number of patients with available data on the
combination of HER2 double-block and hormonal therapy as
a maintenance strategy. Our data fully support that the use of
all treatments available to the clinicians in this subset of
patients positively affects the outcome of our patients.
Patients and methods
We retrospectively identified 264 consecutive Caucasian,
female patients from the real life setting who received pertu-
zumab/trastuzumab and taxanes (docetaxel or paclitaxel) at 22
Italian oncologic centres. None of these patients had been
previously included in randomized clinical trials. The follow-
up was stopped in September 2017, that is, when a median
follow-up of at least 12 months was reached, and statistical
analysis performed. Our primary objective was to evaluate the
efficacy of pertuzumab, trastuzumab and taxane (docetaxel/
paclitaxel)-based regimens in a non-selected patient popula-
tion. Secondarily, we aimed to explore the efficacy of pertu-
zumab-based treatment in pre-defined subsets of patients
identified according to patient- and disease-related key
features.
Pertuzumab, trastuzumab and docetaxel or paclitaxel, were
administered intravenously according to the current guide-
lines, until disease progression or death, unacceptable toxicity,
or patient refusal. Patients not progressing while on che-
motherapy treatment were usually given maintenance pertu-
zumab and trastuzumab. Patients with hormonal receptor
positive tumors were included in the analysis independently
on the administration of maintenance endocrine therapy.
Treatment efficacy was evaluated every 3 months as standard
practice according to RECIST criteria. Our study was
approved by the Ethic Committees of the coordinating and
satellite centres and conducted according to the Helsinki
Declaration. All the patients released a written informed
consent.
Data collection
Medical records were retrieved for demographic, clinical
and molecular features, previous treatments and related
outcomes, number and site of metastases at the time of
treatment starting, objective response, date at disease pro-
gression and date at last follow-up or death. Pathology
assessment was performed in surgical specimens of primary
tumors at the participating centers. When missing, the
molecular features were centrally evaluated in formalin-
fixed, paraffin-embedded tissue sections. In 93 patients
(35.2%), a re-biopsy of a single metastatic lesion was per-
formed. HER2 status was evaluated by immunohistochem-
istry, and expression level 3+ (DAKO Herceptest) was
considered positive. Fluorescence, chromogenic, or silver
in situ hybridization (FISH, CISH, SISH, respectively) were
performed to identify HER2 amplification in case of HER2
2+ staining. Anonymized data were entered into a dedicated
database.
Statistical analysis
Variables were assessed by Pearson Chi-Square test or Fisher
Exact test. Their impact on survival was tested in Cox uni/
multivariate models. The multivariate Cox hazard model was
built using stepwise regression (forward selection). Enter and
remove limit were p = 0.10 and p = 0.15. The following
variables were considered: age, ECOG Performance Status
(PS), histology, ki67 percent expression (%), molecular sub-
type, stage at diagnosis, type of surgery, adjuvant and neoad-
juvant treatment, disease-free survival, trastuzumab
pretreatment, type and number of metastatic sites and objec-
tive response. Survival was addressed by the Kaplan–Meier
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method and log-rank test. Significance was defined at
p ≤ 0.05 level.
The effect of covariates potentially acting as confounders in
a non-randomized cohort was minimized by propensity score
match, which allowed to create patient groups who were
similarly likely to receive a given treatment based on their
baseline characteristics.27 The SPSS software was used for
statistical evaluations (SPSS version 21.0, SPSS Inc., Chicago,
Illinois, USA).
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